ReviewJCO precision oncology2019
Precision Oncology and the Universal Health Coverage System in Japan.
Review in JCO precision oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine.Pathology international · 2021Guideline
- Landscape of cancer genomics and precision oncology in Japan, South Korea, China, and Australia.The Lancet regional health. Western Pacific · 2026Review
- Large-scale Genomic Landscape and Clinical Outcomes of De Novo and Treatment-emergent Neuroendocrine Prostate Cancer.European urology open science · 2026Article
- A prioritization framework for BRCA1/2 variants of uncertain significance identified by comprehensive genomic profiling.European journal of human genetics : EJHG · 2026Article
- Bridging the distance in precision oncology: a nationwide survey on institutional perspectives toward telemedicine and decentralized trials in Japan.International journal of clinical oncology · 2026Article
- Clinicogenomic Landscape of Histologic Subtypes in Ovarian Cancer: Real-World Evidence From a Japanese Nationwide Cohort.JCO precision oncology · 2026Article
- TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.Breast cancer research : BCR · 2026Article
- Real-world clinical utility and challenges of comprehensive genomic profiling for advanced solid tumors in a community health institution.International journal of clinical oncology · 2026Article
- Genomic landscape and clinical impact of BRCA1/2 pathogenic variants in metastatic castration-resistant prostate cancer.NPJ precision oncology · 2026Article
- Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.Cancer science · 2026Article
- Article
- Prognostic impact of genomically matched therapy for solid cancers using real-world data from a provincial hospital in Japan.International journal of clinical oncology · 2026Article
- Earlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype-Matched Therapy: A Prospective Single-Institution Study.Obstetrics and gynecology international · 2026Article
- Nationwide Real-World Usage of Blood-Based (Liquid) Biomarker Testing in Japan.Cancer science · 2025Article
- Article
- Clinical utility and characteristics of comprehensive genomic profiling tests in patients with gynecologic cancer: a multi-institutional survey in Kinki District, Japan.International journal of clinical oncology · 2025Article
- Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance ofESMO gastrointestinal oncology · 2025Article
- Patient and physician preferences for cancer panel testing in Japan: a best-worst scaling study.BMJ open · 2025Observational
- Real-World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in Sarcoma.Cancer medicine · 2025Article
- Lynch Syndrome Screening and Surveillance Trends among Gastroenterologists in Japan: A Questionnaire Survey-based Analysis.Internal medicine (Tokyo, Japan) · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although precision oncology is transforming clinical management of patients with cancer, many hospitals face challenges to effectively implement precision oncology. In addition, the cost and time exerted for genomic profiling needs to be balanced with expectations of benefit for each patient. This article summarizes the effort to implement precision oncology in Japan. The most promising development is that tests to profile the genomes of select cancers are now fully covered by the national health insurance system. In May 2019, two gene panels were approved with reimbursement: FoundationOne CDx Cancer Genomic Profile and OncoGuide NCC Oncopanel System, the latter of which was developed in Japan. To make better use of scarce resources, the reimbursement is restricted to patients with solid tumors that have progressed on standard chemotherapy, rare tumors, or tumors of unknown primary. To centralize Japanese precision oncology, the government designated approximately 170 hospitals and stratified them to three layers on the basis of their roles. In addition, Japan's National Cancer Center launched a Center for Cancer Genomics and Advanced Therapeutics (C-CAT) that collects genomic information and clinical characteristics of patients who received genomic profiling tests. C-CAT is expected to be the central data repository, to match patients with clinical trials, and to assist translational research. The centralized system under the national health insurance system could be a double-edged sword. Although tight regulation may make it hard to keep up with the rapid development of precision oncology, a federated ecosystem for sharing clinical and genomic data will be a precious asset and allow for shared access to data. Access to unapproved drugs and administrative support from C-CAT will be keys for Japanese precision oncology to meet its full potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.